Alzinova (ALZ) Investing in Life Science 2025 summary

Market overview and unmet need

• Alzheimer's disease affects 50 million people globally, expected to double to 100 million in 25 years, with a $1.3 trillion annual cost and 8%-12% market CAGR.

• Current treatments require frequent hospital visits and are costly, while a vaccine approach could reduce costs to 2% of current therapies.

Company and pipeline highlights

• Founded in 2011 in Gothenburg, the company has two candidates: ALZ-101 (vaccine, Phase 2 ready) and ALZ-201 (antibody, preclinical).

• ALZ-101 offers simple intramuscular injections three times a year, potentially administered at home or in primary care.

• Business model targets pharma partnerships pre-Phase 2, with income from milestones and royalties.

Scientific innovation and clinical data

• Focuses on amyloid beta 42 oligomers, shown to be toxic in Alzheimer's, and has stabilized these for drug development.

• Active immunization approach aims for long-lasting immunity and potential preventive use.

• Phase 1b trial (32 subjects) showed strong safety, tolerability, and robust immune response, with only mild injection site reactions.

• Cognitive endpoints indicated disease stability in treated patients, supported by biomarker data.

• No ARIA-E brain edema events observed, suggesting broader patient eligibility compared to current treatments.